WallStreetZenWallStreetZen

NASDAQ: ALEC
Alector Inc Stock

$4.59+0.02 (+0.44%)
Updated Jun 24, 2024
ALEC Price
$4.59
Fair Value Price
N/A
Market Cap
$442.41M
52 Week Low
$3.66
52 Week High
$9.07
P/E
-3.33x
P/B
2.47x
P/S
5.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$96.41M
Earnings
-$120.61M
Gross Margin
100%
Operating Margin
-120.63%
Profit Margin
-125.1%
Debt to Equity
2.55
Operating Cash Flow
-$197M
Beta
1.41
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALEC Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALEC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALEC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALEC is good value based on its book value relative to its share price (2.47x), compared to the US Biotechnology industry average (6.29x)
P/B vs Industry Valuation
ALEC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALEC due diligence checks available for Premium users.

Be the first to know about important ALEC news, forecast changes, insider trades & much more!

ALEC News

Valuation

ALEC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.33x
Industry
-6.96x
Market
30.03x

ALEC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.47x
Industry
6.29x
ALEC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALEC's financial health

Profit margin

Revenue
$15.9M
Net Income
-$36.1M
Profit Margin
-227%
ALEC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALEC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$635.5M
Liabilities
$456.6M
Debt to equity
2.55
ALEC's short-term assets ($581.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALEC's short-term assets ($581.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALEC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALEC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$61.3M
Investing
-$11.8M
Financing
$71.1M
ALEC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALEC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALEC$442.41M+0.44%-3.33x2.47x
VERV$443.34M-0.19%-1.84x0.76x
EYPT$443.76M+0.59%-4.71x1.78x
ANNX$440.81M-4.22%-3.27x1.68x
LXRX$445.69M-2.16%-2.18x1.54x

Alector Stock FAQ

What is Alector's quote symbol?

(NASDAQ: ALEC) Alector trades on the NASDAQ under the ticker symbol ALEC. Alector stock quotes can also be displayed as NASDAQ: ALEC.

If you're new to stock investing, here's how to buy Alector stock.

What is the 52 week high and low for Alector (NASDAQ: ALEC)?

(NASDAQ: ALEC) Alector's 52-week high was $9.07, and its 52-week low was $3.66. It is currently -49.37% from its 52-week high and 25.41% from its 52-week low.

How much is Alector stock worth today?

(NASDAQ: ALEC) Alector currently has 96,384,562 outstanding shares. With Alector stock trading at $4.59 per share, the total value of Alector stock (market capitalization) is $442.41M.

Alector stock was originally listed at a price of $18.00 in Feb 7, 2019. If you had invested in Alector stock at $18.00, your return over the last 5 years would have been -74.5%, for an annualized return of -23.91% (not including any dividends or dividend reinvestments).

How much is Alector's stock price per share?

(NASDAQ: ALEC) Alector stock price per share is $4.59 today (as of Jun 24, 2024).

What is Alector's Market Cap?

(NASDAQ: ALEC) Alector's market cap is $442.41M, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alector's market cap is calculated by multiplying ALEC's current stock price of $4.59 by ALEC's total outstanding shares of 96,384,562.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.